1. Potent Amphiphilic Poly(Amino Acid) Nanoadjuvant Delivers Biomineralized Ovalbumin for Photothermal-Augmented Immunotherapy.
- Author
-
Zhao X, Zheng Y, Liu Y, Li Y, Lin Z, Li H, Zhang J, Zhao M, Zhang K, Li Y, Shen H, Zhao N, and Xu FJ
- Subjects
- Animals, Mice, Polylysine chemistry, Polylysine pharmacology, Polyglutamic Acid chemistry, Mice, Inbred C57BL, Manganese Compounds chemistry, Manganese Compounds pharmacology, Oxides chemistry, Oxides pharmacology, Melanoma, Experimental immunology, Melanoma, Experimental therapy, Melanoma, Experimental pathology, Photothermal Therapy, Cancer Vaccines chemistry, Cancer Vaccines immunology, Surface-Active Agents chemistry, Surface-Active Agents pharmacology, Tumor Microenvironment drug effects, Tumor Microenvironment immunology, Female, Ovalbumin chemistry, Ovalbumin immunology, Immunotherapy, Adjuvants, Immunologic pharmacology, Adjuvants, Immunologic chemistry, Nanoparticles chemistry
- Abstract
Cancer nanovaccines have emerged as an indispensable weapon for tumor treatment. However, insufficient immunogenicity and immunosuppression hamper the therapeutic effects of nanovaccines. Here, biodegradable nanovaccines (OMPP) composed of ovalbumin (OVA)-manganese oxide nanoparticles, amphiphilic poly(γ-glutamic acid) (γ-PGA), and ε-polylysine (PL) are constructed to realize enhanced cancer immunotherapy. Interestingly, amphiphilic γ-PGA and PL could serve as both carriers and immunoadjuvants to promote the cytosolic delivery of antigens and enhance the maturation of dendritic cells. Additionally, taking advantage of the photothermal property of OMPP, immunogenic cell death and in situ release of tumor-associated antigens can be triggered under near-infrared light irradiation for personalized tumor treatment. Moreover, OMPP nanovaccines can efficiently alleviate tumor hypoxia and downregulate programmed death-ligand 1 expression to reprogram the immunosuppressive tumor microenvironment. OMPP-mediated therapy has been shown to provoke robust immune responses to suppress B16-OVA melanoma and prevent postsurgical tumor recurrence. This work presents a facile strategy for the fabrication of nanovaccines by integrating carrier and adjuvant while exploring the inherent properties to promote antigen release and modulate immunosuppression, which demonstrates great potential for effective cancer immunotherapy.
- Published
- 2024
- Full Text
- View/download PDF